Disease Landscape and Forecast Insights

Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple types of difficult-to-treat seizures. Only a handful of…

Postoperative pain is one of the key segments comprising the larger market for acute pain therapies. It has experienced strong growth over the past decade owing to the uptake of Pacira BioSciences…

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &…

Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…

The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval of hormonal agents such as Zytiga (Johnson & Johnson), Xtandi (…

Numerous antidepressant therapies are available to treat major depressive disorder (MDD), many of which have long been generic and are entrenched in medical practice. However, most current…

PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…

Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) have transformed the treatment of ankylosing spondylitis (AS…

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastatic setting, remain limited. Cyramza (Eli Lilly)…

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis , the most prevalent form of MS. Nevertheless…